Abstract:【Objective】 To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting liver tumor in order to improve the tissue distribution of paclitaxel in vivo,and to promote the safety and the anti-tumor efficacy of paclitaxel administration.【Methods】 A novel galactosylated lipid,(5-Cholesten-3β-y1) 4-oxo-4-[2-(1actobionyl amido) ethylamido] butanoate(CHS-ED-LA),was incorporated in the liposomes for liver targeting.Paclitaxel was uptaken into conventional liposomes(CL) and galactosylated liposomes(GalLs) by transmembrane ammonium sulfate gradient method.The pharmacokinetics,tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol,conventional liposomes(CL) or galactosylated liposomes(GalLs) in tumor-bearing nude mice.The maximum tolerance doses(MTDs) of two different formulations of paclitaxel were determined in Kunming mice.【Results】 Transmission electron microscopy(TEM) image showed that both conventional liposomes(CL) and galactosylated liposomes(GalLs) shaped regularly round and dispersed uniformly,and these two particle sizes were(78.5±27.8) nm and(88.6±32.5) nm,respectively.The encapsulation efficiencies of both conventional liposomes(CL) and galactosylated liposomes(GalLs) were at or above 25%.In vivo,the circulation time of conventional liposomes(CL) and galactosylated liposomes(GalLs) was longer than taxol,and the pharmacokinetic parameters of conventional liposomes(CL) and galactosylated liposomes(GalLs) were similar.Tumor-targeting efficiency of galactosylated liposomes(GalLs) was better than that of S conventional liposomes(CL) or taxol,as well as the tissue distribution of galactosylated liposomes(GalLs) in normal organs was at a relatively low level as compared with that of conventional liposomes(CL) or taxol,in contribution to RGD specifically targeting tumors.The MTDs of conventional liposomes(CL) and galactosylated liposomes(GalLs) were higher than that of taxol.Compared with conventional liposomes(CL) and taxol with the same dose of paclitaxel,the anti-tumor efficacy of galactosylated liposomes(GalLs) was improved significantly(P <0.05);and the mice received galactosylated liposomes(GalLs) therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.【Conclusion】 The liver cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo.

The cellular uptake and anti-tumor activity of conjugated linoleic acid-paclitaxel-loaded iRGD-modified lysolipid-containing thermosensitive liposomes

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.

Preparation of thermosensitive liposomes containing paclitaxel and their anticancer effect

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Integrin-targeted paclitaxel nanoliposomes for tumor therapy

The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat.

Synergistic Anti-Tumor Activity of Paclitaxel-Incorporated Conjugated Linoleic Acid-Coupled Poloxamer Thermosensitive Hydrogel in Vitro and in Vivo

Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings.

Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes

A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma

Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells

Rgd-Based Strategies for Improving Antitumor Activity of Paclitaxel-Loaded Liposomes in Nude Mice Xenografted with Human Ovarian Cancer

Tumor-targeted Paclitaxel Delivery and Enhanced Penetration Using TAT-decorated Liposomes Comprising Redox-Responsive Poly(ethylene Glycol).

[Cellular Toxicity and Anti-Tumor Efficacy of Irgd Modified Doxorubixin Loaded Sterically Stabilized Liposomes].

Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo

The Antitumor Activity of a Doxorubicin Loaded, Irgd-Modified Sterically-Stabilized Liposome on B16-F10 Melanoma Cells: in Vitro and in Vivo Evaluation

Study on the Mechanism of Action of Paclitaxel-Loaded Polylactic-co-glycolic Acid Nanoparticles in Non-Small-Cell Lung Carcinoma Cells

Peptide Ligand and Peg-Mediated Long-Circulating Liposome Targeted to Fgfr Overexpressing Tumor in Vivo

The anti-tumor effects of liver cancer-targeting long-circulating paclitaxel-containing Galactosylated liposomes

Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo